You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

 

Online download statistics by month:

Online download statistics by month: May 2024 to January 2026

AbstractFullPdf
May 202410851090435
Jun 20241049981294
Jul 20243573601592
Aug 2024192187117
Sep 20242132202288
Oct 2024182182106
Nov 202424224398
Dec 2024276283147
Jan 2025418422171
Feb 2025445446151
Mar 2025215217166
Apr 2025311314186
May 2025263264153
Jun 202513213385
Jul 2025440
Aug 2025110
Nov 2025550
Jan 2026001
Total539053525990